A new investigational antibiotic cream has demonstrated a high cure rate of 81% for cutaneous leishmaniasis, with only minor reactions reported. The treatment offers a safe and effective option for patients, potentially replacing toxic and painful treatments.
A new Ebola virus study demonstrates a proof-of-concept for using monoclonal antibodies to prevent lethal disease in rhesus macaques. The plant-based production method offers potential for an economical and effective medical countermeasure.
A new study found that the RV144 vaccine was effective in preventing certain HIV viruses, particularly those carrying specific genetic footprints. The vaccine's immune response targeted the Env-V2 region, leading to increased efficacy of up to 80 percent.
Researchers have successfully protected laboratory animals from lethal hantavirus disease using a DNA vaccine and duck eggs. The study demonstrates the feasibility of this novel approach, which could supplement or replace existing treatments for HPS.
Laboratory studies of the RV144 vaccine have found that antibodies specific to a particular region of the HIV outer coat correlate with lower infection rates among vaccinated individuals. In contrast, high levels of a different type of envelope binding antibody appear to offer less protection against HIV.
US Army researchers have successfully tested antibody-based therapies in monkeys infected with Ebola and Marburg viruses, demonstrating full protection even when treatment was delayed until two days post-infection. This breakthrough provides proof-of-concept for developing filovirus therapies for human use.
A new anthrax capsule vaccine protects monkeys from lethal infection, offering a non-toxin alternative to current vaccines. The vaccine works by inducing anti-capsule antibody responses and is expected to be effective against vaccine-resistant strains of anthrax.
A recent study published in Nature shows that a novel combination of HIV vaccine candidates provides partial protection against Simian Immunodeficiency Virus (SIV) infection in rhesus monkeys. The optimal vaccine combinations also substantially reduced the amount of virus in the blood.
Researchers identified Niemann-Pick C1 as a critical cellular protein for Ebola virus entry, allowing scientists to develop antiviral drugs. The discovery offers a promising strategy to combat the deadly virus.
Researchers developed novel antisense therapies that protected monkeys infected with deadly Ebola or Marburg viruses, with survival rates over 90%. The treatments were administered up to one hour after exposure and showed promise for treating accidental infections in laboratory or hospital settings.
Scientists have successfully prevented monkeys exposed to the deadly Ebola virus from dying of hemorrhagic fever using a genetic material-based treatment. The study suggests that such protection could also be possible in humans, offering new hope for combating the highly contagious and lethal disease.
Researchers at USAMRIID have found a novel approach to defeating the anthrax pathogen by inducing high levels of CapD enzyme, releasing capsule fragments and leaving bacteria vulnerable to immune destruction. This breakthrough could lead to new treatment options for anthrax infection.
Research published in Cell Host and Microbe reveals a minor reduction in CD45 levels provides protection against both Ebola virus and Bacillus anthracis. Mice expressing reduced CD45 levels showed enhanced viral clearance and increased protection against infection.
Researchers found that a vaccine combined with short-term antibiotic treatment can protect nonhuman primates from inhalational anthrax. The study suggests that this combination may be crucial for successful defense against large-scale anthrax attacks, minimizing the risk of adverse events and improving public health management.
A new experimental vaccine has been shown to protect nonhuman primates against Marburg virus infection, even when administered after exposure. The study found that all treated monkeys survived for at least 80 days, while controls succumbed to the disease within 12 days.
Researchers used novel antisense drugs to interrupt normal Ebola virus replication, showing protection in non-human primates. The therapy directly targets the virus and may be more potent than current anti-viral treatments.
The US Army's Gamma Phage Assay has been approved by the FDA for human use within the Laboratory Response Network (LRN), enabling early detection of anthrax bioterrorism threats. This test, developed with CDC support, is a classical bacteriological method that uses a virus to identify B. anthracis.
A new experimental vaccine has shown promising results in protecting nonhuman primates from Lassa fever. The vaccine, developed using a non-pathogenic form of vesicular stomatitis virus as a carrier, has been successfully tested with all vaccinated monkeys surviving infection.
Researchers have developed a new vaccine that is 100 percent effective in protecting monkeys from infection with deadly viruses Ebola and Marburg. The vaccine targets dendritic cells, which are the same cells attacked by these viruses.
Researchers have developed a vaccine that targets the anthrax capsule, providing improved protection against experimental infection. The study showed that mice vaccinated with the capsule vaccine survived challenge doses of spores, demonstrating the effectiveness of this new approach.
A research team led by Peter B. Jahrling has successfully developed a nonhuman primate model of smallpox infection in monkeys. The study demonstrates that variola virus can produce lethal disease in monkeys, providing valuable insight into the pathogenesis of smallpox.
The study found that USAMRIID's biosafety and medical management program effectively prevented laboratory-acquired infections, with only five confirmed cases in a fourteen-year period. The review emphasized the importance of vaccination and early evaluation of potential exposures.
A novel protein vaccine candidate has demonstrated full protection against a lethal aerosol challenge with ricin toxin in mice, offering a promising solution to bioterrorism threats. The vaccine, RTA 1-33/44-198, was designed using molecular modeling and protein engineering techniques.
Researchers developed a DNA vaccine that protected nonhuman primates from both smallpox and monkeypox, offering a safer alternative to existing live virus vaccines. The vaccine used four genes from vaccinia virus and was shown to elicit a robust immune response in primates.
A team of scientists has successfully tested a new smallpox vaccine that shows promise as an alternative to the existing Dryvax vaccine. The MVA vaccine was found to elicit equivalent or higher immune responses in nonhuman primates, providing protection against monkeypox.
Dr. Peter Jahrling has been recognized by the American Association for the Advancement of Science (AAAS) as a Fellow for his contributions to vaccine development and medical defense against infectious diseases. He is credited with advancing research on filovirus and poxvirus threats.
Researchers at USAMRIID successfully detected variola virus in a 50-year-old tissue sample using integrated diagnostic methods. The study demonstrates the capabilities of modern molecular diagnostics in identifying biological agents, which is crucial for national defense and infectious disease research.
Researchers have discovered a common pharmacophore that can be used to develop more potent and selective lethal factor inhibitors. This breakthrough holds promise for developing new anthrax therapies, particularly in cases where antibiotics are not effective.
A new drug, rNAPC2, has shown promising results in treating Ebola by slowing coagulopathy and death in primates. The treatment targets the disease process rather than replicating the virus, offering a potential breakthrough in combating the deadly disease.
Researchers at USAMRIID have developed Ebola virus-like particles (VLPs) that induce both cell-mediated and humoral immunity in mice, providing 100% protection against lethal challenge. The VLPs, resembling infectious viral particles without genetic material, offer a promising vaccine platform for Ebola and other viruses.
Researchers have identified compounds that inhibit the enzymatic action of botulinum neurotoxin serotype A light chain (BoNT/A LC), a crucial step towards developing new therapeutics. The findings hold promise for treating botulism and other muscle dysfunctions in humans.
Researchers at the US Army Medical Research Institute of Infectious Diseases have developed a hantavirus vaccine that elicited a potent neutralizing antibody response in rhesus macaques. The vaccine, which uses a naked DNA approach, also provided protection against hamster infection when administered after exposure.